AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2898052
Drug: B subunit
RxNorm normalized name: Modified Cholera toxin B subunit
DrugBank: Modified Cholera toxin B subunit (DB18557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B subunit killed whole-cell (BS-WC) vaccine
Trial: 2898052
Drug: Killed whole-cell-only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed whole-cell-only (WC) vaccine
Trial: 28120485
Drug: Triazolam 0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.375 mg (positive control)
Trial: 25399551
Drug: Dabrafenib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabrafenib (150 mg twice daily) and trametinib (2 mg once daily)
Trial: 29724167
Drug: Vemurafenib (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib (960 mg twice daily)
Trial: 23234813
Drug: Oral recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral recombinant human PTH(1‐31)NH(2) 5mg once daily for 24 weeks
Trial: 23234813
Drug: Open-label subcutaneous
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label subcutaneous teriparatide
Trial: 17263088
Drug: Soft drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft drink containing 0.232 g of ginseng and 2 g of ginkgo extract
Trial: 10931020
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with MPFF
Trial: 9283511
Drug: meta‐chlorophenylpiperazine (m‐CPP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meta‐chlorophenylpiperazine (m‐CPP) (1.0 mg/kg)
Trial: 7685921
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination (DRE) and transrectal ultrasonography (TRUS)
Trial: 3106458
Drug: Acute hpGRF‐44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hpGRF‐44 iv administration (1 microgram/Kg bw)
Trial: 3106458
Drug: Sc administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sc administration of the same dose at 4‐h intervals by a programmable portable pump
Trial: 22489255
Drug: Risperidone (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2.0 mg)
Trial: 18669979
Drug: ezetimibe/simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20 mg/day + fenofibrate 160 mg/day
Trial: 18669979
Drug: fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 160 mg/day
Trial: 16394908
Drug: Intravenous tPA
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tPA and heparin
Trial: 8638025
Drug: Empiric amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric amiodarone therapy
Trial: 8638025
Drug: Type-I antiarrhythmic
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type-I antiarrhythmic drugs
Trial: 8638025
Drug: Mixed group
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed group of antiarrhythmic drugs
Trial: 31738072
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for AUD, duration: 12 weeks
Trial: 24446216
Drug: Fufang Xuelian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Xuelian Burn Ointment (FXBO) plus common burn wound therapy
Trial: 24446216
Drug: Common burn
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common burn wound therapy
Trial: 8472519
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg tablet of ST‐679
Trial: 8472519
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg capsule of ST‐679
Trial: 31926340
Drug: Apremilast 40
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast 40 mg
Trial: 31926340
Drug: Apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 30 mg and 40 mg
Trial: 22757665
Drug: 1540 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1540 nm non-ablative fractional laser (NAFL) treatment, 4 treatments at monthly intervals
Trial: 22757665
Drug: 1540 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1540 nm non-ablative fractional laser (NAFL) treatment
Trial: 21576636
Drug: sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib (400 mg orally twice a day) plus erlotinib (150 mg orally daily)
Trial: 21576636
Drug: placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus erlotinib (150 mg orally daily)
Trial: 10711927
Drug: Ondansetron (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (24 mg daily)
Trial: 15321287
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine patient‐controlled analgesia (PCA)
Trial: 15321287
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine and Intravenous morphine patient‐controlled analgesia (PCA)
Trial: 3899048
Drug: Clomipramine hydrochloride
RxNorm normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine hydrochloride (mean dosage, 141 mg/day)
Trial: 29790278
Drug: Split-dose 4-L
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split-dose 4-L polyethylene glycol (4-SD)
Trial: 29790278
Drug: Routine, morning-only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine, morning-only 2-L polyethylene glycol (2-MO)
Trial: 14766688
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 1 g
Trial: 3110248
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP), 200 micrograms twice daily
Trial: 3110248
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG), 2 mg four times daily
Trial: 3110248
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (BDP and SCG)
Trial: 27242121
Drug: 30mg zinc
RxNorm normalized name: zinc citrate 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg zinc sulphate dispersible tablet, once daily for six months
Trial: 27242121
Drug: Placebo, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily for six months
Trial: 20592230
Drug: PHMB-preserved solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHMB-preserved solution
Trial: 16644196
Drug: Hochu-ekki-to (HET)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hochu-ekki-to (HET) 7.5 g/day for two weeks
Trial: 16644196
Drug: Placebo (indistinguishable)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (indistinguishable) 7.5 g/day for two weeks
Trial: 16249679
Drug: Combined spinal‐epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spinal‐epidural technique with 27‐gauge Whitacre needle dural puncture without subarachnoid drug administration
Trial: 10667430
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months combined androgen blockade therapy (n = 18)
Trial: 10667430
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months combined androgen blockade therapy (n = 22)
Trial: 1858189
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg administered as an enema
Trial: 6136287
Drug: Inert medication
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert medication (Control)
Trial: 27986742
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment for 6 weeks
Trial: 23755902
Drug: Buffered saline
RxNorm normalized name: Phosphate Buffered Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered saline solution (in vitro)
Trial: 14763497
Drug: Qb above
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qb above 250 ml/min
Trial: 14763497
Drug: Increased Qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased Qd from 500 to 800 ml/min
Trial: 8404176
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline 0.125 mg
Trial: 8404176
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline 1.5 mg
Trial: 3492486
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg twice daily for ten days)
Trial: 3492486
Drug: Co-trimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole twice daily for ten days)
Trial: 21540741
Drug: GW842166 800
RxNorm normalized name: GW842166
DrugBank: GW842166 (DB11903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW842166 800 mg
Trial: 21540741
Drug: GW842166 100
RxNorm normalized name: GW842166
DrugBank: GW842166 (DB11903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW842166 100 mg
Trial: 18510961
Drug: Flavanol-rich cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanol-rich cocoa (321 mg flavanols per dose)
Trial: 18510961
Drug: Nutrient-matched control
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient-matched control (25 mg flavanols per dose)
Trial: 18510961
Drug: Flavanol-rich cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavanol-rich cocoa (single acute dose)
Trial: 9315986
Drug: Pindolol 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 7.5 mg/day
Trial: 8447613
Drug: Subarachnoid morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid morphine 0.25 mg with adrenaline 200 micrograms (group MA)
Trial: 8447613
Drug: Subarachnoid morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid morphine 0.25 mg without adrenaline (group M)
Trial: 21189431
Drug: Atorvastatin, 10
RxNorm normalized name: Amlodipine Besylate-Atorvastatin, 10 mg-80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, 10 mg daily for 2 months
Trial: 21189431
Drug: Lovastatin, 40
RxNorm normalized name: Lovastatin, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin, 40 mg daily for 2 months
Trial: 21189431
Drug: Simvastatin, 20
RxNorm normalized name: Simvastatin, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 20 mg daily for 2 months
Trial: 21189431
Drug: Atorvastatin, Simvastatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, Simvastatin, Lovastatin
Trial: 14961173
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application of Dovobet (calcipotriol 50 micrograms/gram and betamethasone dipropionate 0.5 milligrams/gram)
Trial: 14961173
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of Dovobet
Trial: 10660736
Drug: 5-fluorouracil (5-FU),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5-FU), 300 mg/day
Trial: 10660736
Drug: Cyclophosphamide (CPA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (CPA), 150 mg/day
Trial: 3085464
Drug: Nifedipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (60 to 90 mg/day)
Trial: 23468176
Drug: Etanercept at
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept at 0.4 mg/kg per week for the first year, then 0.4 mg/kg per month for the second year
Trial: 21112538
Drug: liposome‐encapsulated 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposome‐encapsulated 2% ropivacaine gel (RL2)
Trial: 20542419
Drug: 20% benzocaine
RxNorm normalized name: BENZOCAINE 200 mg in 1 g DENTAL GEL [Ipana 20% Benzocaine Topical]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% benzocaine gel (B20)
Trial: 21112538
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gel (P)
Trial: 21112538
Drug: liposomal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposomal placebo gel (LP)
Trial: 11044164
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (nil-by-mouth regimen)
Trial: 1859906
Drug: Post-relapse tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-relapse tamoxifen therapy
Trial: 1859906
Drug: CMF adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF adjuvant therapy
Trial: 6125172
Drug: Propranolol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (3 x 40 mg)
Trial: 6125172
Drug: Pindolol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (3 x 5 mg)
Trial: 6125172
Drug: Both beta‐adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both beta‐adrenoceptor blockers
Trial: 31827767
Drug: Non-manipulative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-manipulative therapy
Trial: 23867982
Drug: Tamoxifen (TMX)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TMX) 20 mg orally for 3 months
Trial: 16967285
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy (16 sessions over 2 months)
Trial: 16967285
Drug: Pelvic-floor exercises
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic-floor exercises and biofeedback therapy
Trial: 15689088
Drug: DTPa HBV-IPV-Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa HBV-IPV-Hib vaccine at 1 1/2, 3 and 5 months of age
Trial: 15689088
Drug: DTPa-IPV-Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-IPV-Hib vaccine at 1 1/2, 3 and 5 months of age with separate HBV vaccine at 1 and 5 months of age
Trial: 15689088
Drug: DTPa HBV-IPV-Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa HBV-IPV-Hib vaccine
Trial: 11694208
Drug: Bupropion SR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion SR, 150 mg/day
Trial: 9450160
Drug: Pivagabine (450-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivagabine (450-900 mg/d by oral route)
Trial: 8565166
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs as sole therapy
Trial: 7397057
Drug: Brotizolam 0.2
RxNorm normalized name: brotizolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.2 mg
Trial: 7397057
Drug: Brotizolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.4 mg
Trial: 7397057
Drug: Brotizolam 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.6 mg
Trial: 7397057
Drug: Brotizolam 0.2
RxNorm normalized name: brotizolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.2 mg (night)
Trial: 7397057
Drug: Brotizolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.4 mg (night)
Trial: 7397057
Drug: Brotizolam 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.6 mg (night)
Trial: 16949180
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine supplements (30 g/day) for 15 days, initiated at least 3 days before chemotherapy
Trial: 16949180
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine supplements (OGS)
Trial: 11939925
Drug: i.v. diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. diclofenac 75 mg followed by oral diclofenac 150 mg/day for 3 days
Trial: 11939925
Drug: ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoprofen 100 mg followed by oral ketoprofen 300 mg/day for 3 days
Trial: 28345160
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g l-carnitine + carbohydrate (CARN)
Trial: 28345160
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g carbohydrate (CON)
Trial: 27256768
Drug: Preoperative bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative bowel preparation with enema
Trial: 27256768
Drug: Preoperative bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative bowel preparation with suppository
Trial: 22626878
Drug: Routine fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine fluid administration (Group A)
Trial: 22626878
Drug: Restricted fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted fluid administration (Group B)
Trial: 20889234
Drug: Topical hypericin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hypericin with visible light irradiation (8 to 20 J/cm²), applied twice weekly for 6 weeks
Trial: 12494299
Drug: Yoghurt (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoghurt (450 g for 4 months)
Trial: 12494299
Drug: Partially skimmed
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially skimmed milk (450 g for 4 months)
Trial: 7731155
Drug: Ionic contrast
RxNorm normalized name: IONIC CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic contrast agent (meglumine/sodium diatrizoate)
Trial: 7731155
Drug: Ionic contrast
RxNorm normalized name: IONIC CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic contrast agent (meglumine/sodium diatrizoate) with RI
Trial: 7731155
Drug: Nonionic contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonionic contrast agent (iohexol) with RI
Trial: 6626426
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pinacidil (single oral dose)
Trial: 6626426
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pinacidil (mean dose, twice daily for 3‐7 weeks)
Trial: 6626426
Drug: Pinacidil (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil (chronic treatment)
Trial: 30179656
Drug: Piperacillin–tazobactam 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin–tazobactam 4 g/0.5 g at the time of intubation and 12 h later
Trial: 26181769
Drug: Screening group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening group (measuring thyroid function and thyroid antibody in early pregnancy)
Trial: 26181769
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone replacement therapy (for 105 SCH and 4 hypothyroid women in screening group)
Trial: 26181769
Drug: Regular follow‐up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular follow‐up visits (for women in screening group who did not take medicine)
Trial: 21947137
Drug: Risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg delayed-release (DR) weekly (either before or after breakfast)
Trial: 23079690
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg immediate-release (IR) daily
Trial: 19942104
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood therapy (ABT) - gluteal intramuscular reinjection of venous blood three times a week
Trial: 19942104
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - sterile sodium chloride solution
Trial: 12174785
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg quinine twice a day for 3 days (group 1)
Trial: 12174785
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg quinine twice a day for 3 days followed by a total dose of 25 mg chloroquine base over 3 days (group 2)
Trial: 12174785
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg chloroquine base given in 2 daily doses for 3 days (group 3)
Trial: 9844152
Drug: Bicarbonate-buffered peritoneal
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate-buffered peritoneal dialysis solution (34 mmol/liter)
Trial: 9844152
Drug: Lactate-buffered peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate-buffered peritoneal dialysis solution (35 mmol/liter)